Launch and Market Reception of xPloration Partner Access Program
The xPloration Partner Access Program was launched in May 2025 and was well received, with the system awarded Best of Show at the PEGS Conference in Boston.
Within weeks of launch, OmniAb sold and installed an xPloration instrument at a global partner, indicating strong early market interest.
The program has generated a robust pipeline of sales leads, with inquiries from new potential discovery partners interested in accessing xPloration.
Market feedback highlights the platform's unmatched throughput, ease of use, and reliability, positioning it as a key differentiator in lab automation and AI-driven screening.
The company views xPloration as a significant revenue stream, including instrument sales, consumables, and subscription services, supporting diversification and innovation.
A $3 million gain was recorded from the sale of the Kv7 asset to Angelini Pharma, partially offset by an increase in CBR liability.
Cash balance at quarter-end was $41.6 million with $2 million cash used during the quarter.
Net loss for Q2 2025 was $15.9 million or $0.15 per share, compared to a net loss of $13.6 million or $0.13 per share in Q2 2024.
OmniAb reported Q2 2025 revenue of $3.9 million, down from $7.6 million in Q2 2024, primarily due to lower milestone achievements and service revenue declines.
Operating expenses decreased to $20.1 million from $23.9 million year-over-year, driven by reductions in R&D and G&A expenses.
Omnicell's Strategic Transformation to an End-to-End Medication Management Platform
Randall Lipps emphasized Omnicell's shift from a device-centric approach to a comprehensive technology platform integrating automation and intelligence.
The transformation aims to provide high visibility and actionable insights across the entire continuum of care.
This strategic pivot is expected to enhance operational and clinical outcomes, positioning Omnicell as a high-tech enterprise solution provider.
Rapid Adoption and Market Impact of IDEXX inVue Dx Platform
InVue Dx placements reached nearly 2,700 units globally by June 2025, exceeding initial expectations and leading to an increased placement forecast of 5,500 units for 2025.
Early customer feedback highlights the platform's workflow efficiency, rapid turnaround, and AI-powered diagnostic confidence.
InVue Dx is expected to support long-term recurring revenue growth, with upcoming launches like FNA for lumps and bumps.
Demand exceeds expectations, with high customer retention and strong demand for consumables, contributing to a 23% year-over-year increase in premium instrument placements.
The platform is reshaping point-of-care cytology testing, with a focus on high-quality, rapid results that support broader adoption in wellness and diagnostic workflows.
Dafinchi